Steroids in RA: Friend or foe (or both)? Abstract 2000 presents longer-term follow-up data from the recently published GLORIA trial.https://t.co/kNxwYMf59m https://t.co/rzRsZymlz3

RA: MACE Events with Opioids vs. NSAIDs The authors of abstract 1646 assessed MACE (myocardial infarction, stroke, heart failure, CVD death, VTE) and all-cause mortality in new users of opioids vs. matched NSAIDs new users.https://t.co/huz6NyYRlh https://t.co/dNYu7ybFZ5

Diffuse alveolar hemorrhage in antiphospholipid syndrome https://t.co/Fx2fGcaNGS https://t.co/jFHUhvs5xV

Eosinophilia in systemic JIA patients after exposure to biologics Dr. Bella Mehta discusses Abstract 0872 at #ACR22. https://t.co/FI7KfDURr3 https://t.co/FqnqMPHJ3h

Inadequate Dosing of Hydroxychloroquine Leads to Hospitalizations in SLEhttps://t.co/qJ8YbJ2Y6A https://t.co/deZKc1835I

Joint hypermobility linked to depression & anxiety? Longitudinal Study of 6105 kids at age 14 yrs: 19% had generalised joint hypermobility (more in F) *+& assoc w/ depression (OR: 3.53), anxiety (3.14) at age 18 https://t.co/9NrEfwt4L5 https://t.co/JrM2JKUuJ0

SLE preg delivery hospitalizations (77560) was associated with increased risk of CV complications, including preeclampsia [aOR 2.12] , peripartum cardiomyopathy (4.42), CHF (4), arrhythmias (2.2), AKI (7.7), stroke (4.8), VTE (6.9) w/ incr hosp costs https://t.co/PF6P8oDWZB https://t.co/jA2pHcciB1

Xeljanz Cancer Risks Detailed The degree to which the oral rheumatology drug tofacitinib (Xeljanz) seems to promote new malignancies is now fleshed out in the latest, and at least somewhat reassuring, report from a landmark safety study. https://t.co/OG2OkD5Tcw https://t.co/1dZcJ5jDUj

Bimekizumab Efficacy in TNF-Refractory PsA Bimekizumab, a selective inhibitor of IL-17F and IL-17, has shown superior efficacy and safety in a 16 week trial in patients with active PsA who previously failed therapy with TNFi inhibitors. https://t.co/NCJvhmisNe https://t.co/Tk2d7ILHl2

From 1055 new polyarthralgia presentations, 88 (8.3%) Dx w/ psoriatic arthritis. PsA Dx assoc w/ a +FamHx ( OR 4.14), psoriasis (OR=78.94), erosions (OR=5.74), US +power Doppler (OR=7.11). Neg assoc w/ +RF (OR 0.03), +CCP (OR 0.06). https://t.co/YXcqUq9JCi https://t.co/PLuU6cTDab

3388 pts in J Hopkins Scleroderma study found 29% w/ calcinosis (13.5% these w/ heavy burden calcinosis/HBC). Calcinosis assoc w/ diffuse SSc, disease severity (PH, ILD, CVD, GI, renal crisis, myopathy)(OR 2.9- 6.9) & PM/Scl Abs (OR 17.31) https://t.co/ksdPcH9W0O https://t.co/OvI9wytf5H

Oligoarticular PsA: FOREMOST Study Dr. Peter Nash discusses abstract 1018 at ACR22 Convergence. Abstract 1018: Characterization of Joint Distribution and Disease Burden in Patients with Early Oligoarticular PsA: Results from the Ongoing FOREMOST Study https://t.co/3vkUQnpm9F https://t.co/h5OijjETUk